Monday, September 12, 2011
Theraclone Sciences Inc., of Seattle, closed a $10.6 million extension to its Series B financing, bringing the total round to $41 million. Previous investors ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo participated in the round. Proceeds are expected to help advance the company's clinical programs and support ongoing discovery projects using its I-STAR technology platform, which is designed for the rapid screening and identification of rare, therapeutically relevant human antibodies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.